Jazz Pharma

7 results

Avectas’s technology allows cells to be taken from people, often critically ill, and returned to them after they have been genetically engineered to address their illness.

Serial entrepreneur Séamus Mulligan has led a $20 million (€18.3 million) fundraising in an Irish company that hopes to revolutionise the treatment of(...)

Avectas cofounder and chief executive Dr Michael Maguire, with cofounder Dr Shirley O’Dea, chief scientific officer and business development director Dr Gillian Hendy. Photograph: Iain White/Fennells

Serial entrepreneur Seamus Mulligan has led a $10 million (€12 million) fundraising for an Irish business at the cutting edge of cell therapy. Avect(...)

Smurfit Kappa chief executive Tony Smurfit. Photograph: Brenda Fitzsimons

From promising acquisitions to significant asset sales and business exits, the winners for July, August and September of this year’s Irish Times Busin(...)

Séamus Mulligan, chairman and chief executive of Adapt Pharma

Séamus Mulligan, the chairman and chief executive of Adapt Pharma, has been chosen as The Irish Times Business Person of the Month for August, an awar(...)

Profector’s patent-protected electrospraying and electrospinning technology is aimed at research scientists in academic institutions, life sciences companies and government agencies

  Adapt Pharma, the latest venture of serial pharmaceuticals entrepreneur Séamus Mulligan, has invested in a high-tech medical devices bus(...)

Jazz Pharma is based in Ireland following its $500 million acquisition of Azur Pharma in 2012

Jazz Pharma, the specialty drug group based in Ireland following its $500 million acquisition of Azur Pharma in 2012, has reported strong growth in it(...)

Jazz Pharmaceuticals CEO and chairman Bruce Cozadd, with Taoiseach Enda Kenny. Photograph:  Shane O’Neill / Fennells.

Shares in Jazz Pharma dropped over 7 per cent yesterday in US trade as the market digested results that came in slightly below expectations for(...)